Search

Search Bar
01/01/2026 The hidden threat: HBV reactivation in the era of antiretroviral therapy optimization
Domingo, P, Stapleton, JT. The hidden threat: HBV reactivation in the era of antiretroviral therapy optimization. AIDS. 2026; 40(1)DOI:10.1097/QAD.0000000000004369. PMID:41489321. IF:3.100(Q2/4D).
16/12/2025 Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration
Timiryasova, A, Greenberg, L, Domingo, P, Tarr, PE, Egle, A, Martin, C, Mussini, C, Wit, F, Cingolani, A, Lehmann, C, Castagna, A, Petoumenos, K, Sabin, CA, Bonnet, F, Lundgren, J, Bottanelli, M, Hosein, S, Carlander, C, Amstutz, A, Grabmeier-Pfistershammer, K, Garges, H, Marongiu, A, Young, LA, Peters, L, Ryom, L. Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration. Cancers. 2025; 17(24)DOI:10.3390/cancers17244000. PMID:41463249. IF:4.400(Q2/3D).
01/10/2025 A plague like no other: beyond the buboes in Thucydides' account of the Plague of Athens
Domingo, P, Prieto, P, Pons, L. A plague like no other: beyond the buboes in Thucydides' account of the Plague of Athens. CLINICAL MICROBIOLOGY AND INFECTION. 2025; 31(10)DOI:10.1016/j.cmi.2025.05.001. PMID:. IF:8.500(Q1/1D).
01/10/2025 Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO study)
Monforte, A, Imaz, A, Ferrer, J, Piatti, C, Molero, M, Rodríguez, A, Stable, CE, Navarro, M, Prieto, P, Domingo, P, Crespo, M, Güerri-Fernández, R, Moltó, J, Navarro, J. Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO study). HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).
01/10/2025 High effectiveness and rare virologic failure in treatment-experienced individuals on long-acting cabotegravir plus rilpivirine therapy across Europe: Insights from the EuroSIDA study
Peters, L, Bannister, W, Sridhar, G, Gardizi, M, van Frankenhuijsen, M, De Scheerder, MA, Johansen, IS, Viard, JP, Duvivier, C, Bogner, J, Degen, O, Castagna, A, Staub, T, Martinez, E, Domingo, P, Moreno, S, Reikvam, DH, Parczewski, M, Knysz, B, Shivkar, Y, Brown, K, van Wyk, J, Vannappagari, V. High effectiveness and rare virologic failure in treatment-experienced individuals on long-acting cabotegravir plus rilpivirine therapy across Europe: Insights from the EuroSIDA study. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).
01/10/2025 Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, openlabel, non-inferiority trial
Masia, M, Domingo, P, Curran, A, Guerri-Fernandez, R, Bernal, E, Bravo, J, Revollo, B, Macias, J, Tiraboschi, JM, Montejano, R, Amador, C, Garcia-Fraile, L, Blanco, JL, Ryan, P, Torralba, M, Merino, D, Diaz-Brito, V, Galindo, MJ, Ferra, S, Villoslada, A, Losa, JE, Fanjul, FJ, Perez-Stachowski, X, Peraire, J, Portilla, J, de la Fuente, S, Dueñas, C, Vazquez, MJ, Di Gregorio, S, Gil, P, de Miguel, M, Alejos, B, Martinez, E. Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, openlabel, non-inferiority trial. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).